Start-up Australia invests in bone-building tech
Monday, 04 April, 2005
Venture capital fund Start-up Australia Ventures has invested AUD$3 million in junior biotech Caldeon, which is collaborating with the University of Western Australia to optimise osteoporosis drug leads which could reduce bone loss.
"This discovery is a genuine first in the bone metabolism field. This is the first agent to be discovered that specifically stimulates and protects the specialised cells responsible for forming bone," said Prof Ming-Hao Zheng, a co-discoverer of the compounds, along with Dr Jiake Xu and Dr Tony Phan.
Start-up Australia has $55 million under management. Its previous investmest include Alchemia, EvoGenix, Mimetica, Promics, Protagonist, Cortical, Iliad Chemicals and Replikun Biotech
The funding is to be supplied in milestone-based tranches.
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
